Reuters logo
BRIEF-AzurRx Biopharma announces positive MS1819-SD Phase II data in exocrine pancreatic insufficiency
September 27, 2017 / 12:49 PM / 3 months ago

BRIEF-AzurRx Biopharma announces positive MS1819-SD Phase II data in exocrine pancreatic insufficiency

Sept 27 (Reuters) - AzurRx Biopharma Inc

* AzurRx Biopharma and Mayoly-Spindler announce positive MS1819-SD phase II data in exocrine pancreatic insufficiency (epi)

* AzurRx Biopharma Inc - ‍no serious adverse events or notable mild to moderate events have been reported in open-label, ascending dose phase IIA trial​

* AzurRx Biopharma Inc - ‍favorable trends were also observed on other evaluated endpoints​

* AzurRx Biopharma Inc - ‍secondary efficacy endpoints are consistently aligning with CFA data and safety profile of MS1819-SD remains favorable​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below